Thermo Fisher Scientific reports news across scientific instruments, laboratory equipment, diagnostics consumables, life science reagents and pharmaceutical services. Company updates commonly cover operating results, earnings calls, investor presentations and capital deployment through dividends, share repurchases and acquisitions.
Recurring developments also include collaborations tied to laboratory technologies, proteomics, biobank research, analytical instruments and biopharma customer services. Thermo Fisher’s brand portfolio includes Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD, and its completed Clario acquisition added endpoint data solutions for clinical trials to its Laboratory Products and Biopharma Services segment.
Thermo Fisher Scientific, trading under TMO, has announced the pricing of a $1.2 billion bond offering, which includes $600 million in senior notes due 2027 with a 4.800% interest rate and $600 million in senior notes due 2032 with a 4.950% interest rate. The offering is set to close by November 21, 2022, subject to standard conditions. Proceeds will support various corporate purposes, including debt repayment and acquisitions. The offering is managed by BofA Securities, Citigroup, and Deutsche Bank.
Thermo Fisher Scientific (NYSE: TMO) has authorized a substantial share repurchase program, amounting to $4 billion. This initiative allows for the repurchase of shares in the open market or through negotiated transactions, with no expiration date set for the authorization. This strategic move aims to enhance shareholder value and reflects the company's confidence in its strong financial position, supported by an annual revenue of approximately $40 billion.
Thermo Fisher Scientific Inc. (NYSE: TMO) announced a quarterly cash dividend of $0.30 per common share, payable on January 16, 2023, to shareholders on record as of December 15, 2022. The company reported annual revenue of approximately $40 billion, emphasizing its commitment to supporting customers in life sciences research, diagnostics, and therapeutic development. Thermo Fisher continues to lead the industry with innovative technologies and services.
Thermo Fisher Scientific has partnered with Society for Science to present the Junior Innovators Challenge, a leading middle school STEM competition. As the title sponsor, Thermo Fisher aims to enhance student engagement in STEM fields. Nearly 300 affiliated science fairs will nominate top-performing students for the competition, offering over $100,000 in awards, including a $25,000 top prize. This initiative aligns with Thermo Fisher's commitment to equitable access to STEM education.
Thermo Fisher Scientific has announced a significant $1.0 billion share repurchase program for Q4 2022, increasing total buybacks to $3.0 billion for the year. Additionally, the company has entered into an agreement to acquire The Binding Site Group for £2.25 billion (or $2.6 billion), a leader in specialty diagnostics. These moves are part of Thermo Fisher's strategic focus on capital deployment, which will total $6.1 billion in 2022.
Thermo Fisher Scientific (NYSE: TMO) has announced a definitive agreement to acquire The Binding Site Group for £2.25 billion (approximately $2.6 billion). This acquisition enhances Thermo Fisher's specialty diagnostics segment, especially in oncology testing for multiple myeloma, a rapidly growing diagnostics area. The Binding Site is recognized for its Freelite® diagnostic assays, projected to generate over $220 million in revenue for 2022, with an annual growth rate of around 10%. The transaction is expected to complete in the first half of 2023 and will be accretive to adjusted earnings per share by $0.07 in the first full year.
Thermo Fisher Scientific Inc. (NYSE: TMO) reported strong financial results for Q3 2022, with revenue reaching $10.68 billion, a 14% increase. GAAP diluted EPS was $3.79, down from $4.79 in the same quarter last year, while adjusted EPS was $5.08. The company generated $0.44 billion from COVID-19 testing. New product launches, including the Orbitrap Ascend Tribrid mass spectrometer, enhanced their market position. The firm has expanded its manufacturing capabilities and committed to sustainability by sourcing renewable energy.
Thermo Fisher Scientific (NYSE: TMO) has announced the pricing of a ¥109.5 billion offering of yen-denominated senior notes, including 0.853% notes due 2025 and 2.382% notes due 2052. The offering is set to close on or about October 20, 2022. Proceeds will be used for general corporate purposes like debt repayment, acquisitions, or capital expenditures. The notes will pay interest semi-annually and are being managed by Citigroup, Mizuho, MUFG, and SMBC. For further details, investors are encouraged to review related SEC filings.
Thermo Fisher Scientific (NYSE: TMO) will release its Q3 2022 financial results on October 26, 2022, before market opening. A conference call to discuss these results and future expectations will take place at 8:30 a.m. EDT on the same day. The company's revenue is approximately $40 billion, demonstrating its leadership in serving science across various domains including diagnostics and life sciences research. Investors can listen to the call via phone or through the company’s website.
Thermo Fisher Scientific Inc. (NYSE: TMO) has signed an eight-year virtual power purchasing agreement with Enel North America to obtain renewable energy from the Seven Cowboy wind project in western Oklahoma. This agreement will provide around 400,000 megawatt hours of renewable electricity, covering half of the company's U.S. electricity consumption. The project supports Thermo Fisher's commitment to sustainability and a net-zero value chain by 2050, following a $20 million investment in green infrastructure earlier this year.